Antonio Primo DeRosa

Antonio Primo DeRosa

Auto-generated profile, based on publicly available information

Antonio Primo DeRosa

Medical Library, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2016 in Journal of Cancer Survivorship
Verified
Journal Article
Closed access
PDF file
MBMarie Barnett
Marie Barnett
GMGlynnis McDonnell
Glynnis McDonnell
ADAntonio DeRosa
Antonio DeRosa
TSTammy Schuler
Tammy Schuler
EPErrol Philip
Errol Philip
JFJennifer Ford
Jennifer Ford

1 October 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
DSDaniel Spratt
Daniel Spratt
ESElizabeth A. Gordon Spratt
Elizabeth A. Gordon Spratt
SWShenhong Wu
Shenhong Wu
ADAntonio DeRosa
Antonio DeRosa
NLNancy Y. Lee
Nancy Y. Lee
CBChristopher Andrew Barker
Christopher Andrew Barker
Purpose: To perform the first meta-analysis of the efficacy of skin-directed therapies for cutaneous metastases. Methods: MEDLINE, EMBASE, The Cochrane Library, and ClinicalTrials.gov databases were searched for reports of prospective clinical studies published between 1960 and 2013 that assessed the response of skin-directed therapy for cutaneous metastases (47 of 2,955 unique studies were selected). Primary end points of the study were complete and objective response rates. Secondary analyses were preplanned and included subgroup analyses by skin-directed therapy, histology, and recurrence rates. Meta-analyses were performed with random-effect modeling, and extent of heterogeneity between studies was determined with the Cochran Q and I2 tests. Results: After applying exclusion criteria, 47 prospective studies of 4,313 cutaneous metastases were assessed. Five skin-directed therapies were identified: electrochemotherapy, photodynamic therapy, radiotherapy, intralesional therapy, and topical therapy. Among all cutaneous metastases, complete response rate was 35.5% (95% CI, 27.6% to 44.3%) and objective response rate was 60.2% (95% CI, 50.6% to 69.0%). Overall recurrence rate was estimated to be 9.2% (95% CI, 3.7% to 21.2%). Melanoma and breast carcinoma comprised 96.8% of all cutaneous metastases studied and had similar objective response rates (54.5% [95% CI, 48.3% to 60.7%] and 54.0% [95% CI, 48.3% to 59.7%], respectively). Grade ≥ 3 toxicity was reported in less than 6% of patients. Conclusion: Response to skin-directed therapy for cutaneous metastases is high but heterogeneous across treatment modalities, with low rates of recurrence post-treatment. Treatment was generally well tolerated and conferred improvements in quality of life. Standardization of response criteria for cutaneous metastases and treatment algorithms to optimally use the available skin-directed therapies are needed.

24 October 2013 in Journal of Health Psychology
Verified
Journal Article
Closed access
PDF file
AAAllison J Applebaum
Allison J Applebaum
EKElissa A Kolva
Elissa A Kolva
JKJulia R Kulikowski
Julia R Kulikowski
JJJordana D Jacobs
Jordana D Jacobs
ADAntonio DeRosa
Antonio DeRosa
WBWilliam Breitbart
William Breitbart
This systematic review synthesizes the complex literature on prognostic awareness in cancer. A total of 37 studies examining cancer patients’ understanding of their prognosis were included. Prognostic awareness definitions and assessment methods were inconsistent across studies. A surprisingly high percentage of patients (up to 75%) were unaware of their poor prognosis, and in several studies, even their cancer diagnosis (up to 96%), particularly in studies conducted outside of North America. This review highlights surprisingly low rates of prognostic awareness in patients with advanced cancer as well as discrepancies in prognostic awareness assessment, suggesting the need for empirically validated measures of prognostic awareness.

1 July 2017 in Patient Education and Counseling
Verified
Journal Article
Closed access
TDThomas A. D’aGostino
Thomas A. D’aGostino
TAThomas M. Atkinson
Thomas M. Atkinson
LLLauren E. Latella
Lauren E. Latella
MRMadeline Rogers
Madeline Rogers
DMDana Morrissey
Dana Morrissey
PPPatricia A. Parker
Patricia A. Parker

30 September 2015 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
JBJessica L. Burris
Jessica L. Burris
JSJamie L. Studts
Jamie L. Studts
ADAntonio P. DeRosa
Antonio P. DeRosa
JOJamie S. Ostroff
Jamie S. Ostroff
Tobacco use after cancer diagnosis is associated with adverse cancer outcomes, yet reliable prevalence estimates for this behavior are lacking. We conducted a systematic literature review of the prevalence of current tobacco use among individuals with a history of lung or head/neck cancer (CRD #42012002625). An extensive search of electronic databases (MEDLINE, EMBASE, Cochrane Library, CINAHL, PsycINFO, and Web of Science) identified 7,777 potentially relevant articles published between 1980 and 2014 and 131 of these yielded pertinent information. Aggregating results across heterogeneous study designs and diverse patient samples, the overall mean prevalence rate of current tobacco use (mostly cigarette smoking) was 33.0% (median, 31.0%). Among current tobacco users at cancer diagnosis, the mean prevalence rate of current tobacco use (mostly cigarette smoking) was 53.8% (median, 50.3%). In many cases, an operational definition of “current” tobacco use was absent, and biochemical verification of self-reported smoking status was infrequent. These and other observed methodologic limitations in the assessment and reporting of cancer patients' tobacco use underscore the necessity of uniform tobacco use assessment in future clinical research and cancer care. Cancer Epidemiol Biomarkers Prev; 24(10); 1450–61. ©2015 AACR.

22 October 2021 in The American Journal of Emergency Medicine
Verified
Journal Article
Closed access
WHWilliam Haussner
William Haussner
ADAntonio P. DeRosa
Antonio P. DeRosa
DHDanielle Haussner
Danielle Haussner
JTJacqueline Tran
Jacqueline Tran
JTJane Torres-Lavoro
Jane Torres-Lavoro
KSKaushal Shah
Kaushal Shah